Table 3.

Rates of clinical tumor regression in studies of adoptive transfer of tumor-reactive lymphocytes

Type of therapy	Initial rate of objective responses	Subsequent rate of objective responses	Conclusion
LAK cell therapy + high-dose (HD) IL2	44% (11/25) [ref 34]	22% (23/106) [ref 35]	Response rate not better than HD IL2 alone (28 vs 22%), but trend toward improved survival with LAK+IL2 for melanoma (p = 0.064) [refs 36,37]
TIL therapy + HD IL2	55% (11/20) [ref 38]	22% (9/41) [ref 39]	Not better than HD IL2 alone [ref 39]. Median duration of partial responses 4 months [ref 40].
Selected TIL therapy after lymphoablation + HD IL2	51% (18/35) [ref 33]	Pending	Results preliminary